Brian Raj, MD
Neurology · Savannah, GANPI 1508182981
Payments from drug & device makers
Across 35 payments — averaging $19.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$82
- Grifols USA, LLC$61
- Lundbeck LLC$54
- UCB, Inc.$46
- Tanabe Pharma America, Inc.$40
- Acadia Pharmaceuticals Inc$38
- plus $378 from 17 others
What the payments were for
- Food & beverage$699100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 4 | $82 |
| Grifols USA, LLC | 3 | $61 |
| Lundbeck LLC | 2 | $54 |
| UCB, Inc. | 2 | $46 |
| Tanabe Pharma America, Inc. | 2 | $40 |
| Acadia Pharmaceuticals Inc | 2 | $38 |
| AstraZeneca | 2 | $37 |
| Amylyx Pharmaceuticals, Inc. | 1 | $29 |
| Mallinckrodt Enterprises LLC | 2 | $29 |
| Eisai Inc. | 1 | $28 |
| Merz North America, Inc. | 1 | $27 |
| Abbott | 2 | $25 |
| Impel Pharmaceuticals Inc. | 1 | $23 |
| Banner Life Sciences, LLC | 1 | $22 |
| Amgen | 1 | $22 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Neurocrine Biosciences, Inc. | 1 | $21 |
| Greenwich Biosciences, Inc. | 1 | $20 |
| Medtronic | 1 | $17 |
| Neurelis, Inc. | 1 | $15 |
| Aquestive Therapeutics, Inc. | 1 | $14 |
| Bristol Myers Squibb | 1 | $14 |
| MDD US Operations, LLC | 1 | $14 |
How this compares
$699 in reported general payments places this provider in the 35th percentile of 506 neurology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 20 | $9,870 |
| Levetiracetam | 19 | $822 |
| Atorvastatin Calcium | 12 | $145 |
| Amitriptyline Hcl | 15 | $91 |
| Donepezil Hcl | 16 | $69 |
Paid to pharmacies, not to this prescriber.
Other neurology in Savannah
- Victor RosenfeldSavannah$413K
- Robert MacgregorSavannah$403K
- Jonathan LissColumbus$25M
- Marshall NashDecatur$13.6M
- James LahAtlanta$6.8M
- Jonathan GlassAtlanta$5.1M
- Sandeep VaidLawrenceville$4.2M
- Allan LeveyAtlanta$4.2M
- Ben ThrowerAtlanta$3.7M
- Jeffrey EnglishAtlanta$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.